Seegene 미래 성장

Future 기준 확인 4/6

Seegene (는) 각각 연간 35.2% 및 15.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 31.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 5.5% 로 예상됩니다.

주요 정보

35.2%

수익 성장률

31.8%

EPS 성장률

Biotechs 수익 성장	73.5%
매출 성장률	15.7%
향후 자기자본 수익률	5.5%
애널리스트 커버리지	Low
마지막 업데이트	20 Nov 2024

최근 미래 성장 업데이트

Recent updates

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Nov 12

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Aug 10

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Mar 07

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

May 06

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Mar 15

Declining Stock and Solid Fundamentals: Is The Market Wrong About Seegene, Inc. (KOSDAQ:096530)?

Dec 23

Can You Imagine How Elated Seegene's (KOSDAQ:096530) Shareholders Feel About Its 656% Share Price Gain?

Dec 08

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Nov 24

수익 및 매출 성장 예측

KOSDAQ:A096530 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (KRW Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	563,000	63,000	47,000	67,000	1
12/31/2025	466,300	36,600	30,000	50,000	1
12/31/2024	408,700	31,500	53,000	83,000	1
9/30/2024	399,422	29,472	68,855	106,763	N/A
6/30/2024	382,484	23,128	51,929	84,168	N/A
3/31/2024	367,272	-3,461	43,736	74,663	N/A
12/31/2023	367,375	669	63,053	94,932	N/A
9/30/2023	389,688	-2,578	60,269	96,806	N/A
6/30/2023	448,646	-8,971	38,577	80,689	N/A
3/31/2023	492,159	18,719	34,182	92,771	N/A
12/31/2022	853,561	182,139	246,557	319,009	N/A
9/30/2022	1,140,776	343,230	323,190	401,561	N/A
6/30/2022	1,295,241	447,057	496,227	579,900	N/A
3/31/2022	1,470,535	537,404	501,890	574,273	N/A
12/31/2021	1,370,833	536,559	267,913	334,024	N/A
9/30/2021	1,402,531	559,365	307,852	377,100	N/A
6/30/2021	1,424,097	618,128	153,723	331,480	N/A
3/31/2021	1,395,194	633,289	218,235	393,526	N/A
12/31/2020	1,125,216	502,281	207,900	383,157	N/A
9/30/2020	717,254	321,437	79,846	234,884	N/A
6/30/2020	421,777	175,809	73,584	103,313	N/A
3/31/2020	176,245	55,324	10,467	31,529	N/A
12/31/2019	121,953	26,672	22,354	27,141	N/A
9/30/2019	118,445	26,676	18,474	22,290	N/A
6/30/2019	110,402	23,176	18,418	21,008	N/A
3/31/2019	105,861	14,304	13,156	15,670	N/A
12/31/2018	102,265	10,098	10,045	14,010	N/A
9/30/2018	97,975	5,951	11,019	17,831	N/A
6/30/2018	94,684	4,972	N/A	9,870	N/A
3/31/2018	91,979	4,684	N/A	8,555	N/A
12/31/2017	88,920	3,693	N/A	10,115	N/A
9/30/2017	83,092	6,568	N/A	9,699	N/A
6/30/2017	80,817	4,644	N/A	19,233	N/A
3/31/2017	77,285	5,672	N/A	22,227	N/A
12/31/2016	73,694	7,123	N/A	16,557	N/A
9/30/2016	70,519	2,827	N/A	6,916	N/A
6/30/2016	67,973	6,367	N/A	705	N/A
3/31/2016	65,903	6,289	N/A	-607	N/A
12/31/2015	65,137	6,774	N/A	-3,122	N/A
9/30/2015	63,834	9,204	N/A	6,752	N/A
6/30/2015	63,538	8,620	N/A	9,213	N/A
3/31/2015	63,807	8,412	N/A	12,028	N/A
12/31/2014	64,411	9,141	N/A	6,777	N/A
9/30/2014	65,029	8,021	N/A	4,132	N/A
6/30/2014	65,141	8,067	N/A	1,292	N/A
3/31/2014	62,595	9,414	N/A	-5,939	N/A
12/31/2013	58,993	9,573	N/A	-2,893	N/A

애널리스트 미래 성장 예측

수입 대 저축률: A096530 의 연간 예상 수익 증가율( 35.2% )이 saving rate( 2.7% 보다 높습니다. ).

수익 vs 시장: A096530 의 연간 수익( 35.2% ) KR 시장( 28% 보다 빠르게 성장할 것으로 예상됩니다. 28% 연간).

고성장 수익: A096530 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: A096530 의 수익(연간 15.7% ) KR 시장( 9.4% 보다 빠르게 성장할 것으로 예상됩니다. 9.4% 연간).

고성장 수익: A096530 의 수익(연간 15.7% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: A096530 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 5.5 %).

Seegene 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 8.8% to ₩25,000

Consensus EPS estimates fall from profit to ₩18.00 loss

Consensus revenue estimates fall by 21%

Price target decreased to ₩38,667

Consensus revenue estimates fall by 24%

Price target decreased to ₩71,500

Recent updates

Third quarter 2024 earnings released: EPS: ₩36.00 (vs ₩101 loss in 3Q 2023)

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD)

Upcoming dividend of ₩200 per share

Investor sentiment deteriorates as stock falls 16%

Seegene, Inc. Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

New minor risk - Share price stability

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share

Now 20% overvalued

Upcoming dividend of ₩200 per share

Full year 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

New minor risk - Share price stability

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share at 3.5% yield

Price target decreased by 8.8% to ₩25,000

New minor risk - Share price stability

Upcoming dividend of ₩200 per share at 3.7% yield

Consensus EPS estimates fall from profit to ₩18.00 loss

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares.

Upcoming dividend of ₩200 per share at 3.7% yield

Upcoming dividend of ₩200 per share at 3.1% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 21%

Upcoming dividend of ₩400 per share

Investor sentiment deteriorated over the past week

Price target decreased to ₩38,667

Less than half of directors are independent

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Upcoming dividend of ₩200 per share

Consensus revenue estimates fall by 24%

Now 20% undervalued

Investor sentiment improved over the past week

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

Seegene Inc. Develops PCR Test to Detect Monkeypox Virus

Upcoming dividend of ₩400 per share

Now 24% undervalued after recent price drop

Price target decreased to ₩71,500

Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval

Full year 2021 earnings: EPS and revenues miss analyst expectations

Seegene Inc. Unveils New Assay Optimized for On-Site Testing in 'Living with Covid-19' Era

Consensus revenue estimates increase by 13%

Consensus revenue estimates increase by 10%

Investor sentiment improved over the past week

Seegene Inc. to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Seegene Inc. Announces Allplex Sars Cov-2 FluA/FluB/RSV Assay Approved Under Health Canada's Interim Order

Seegene Inc. Unveils Another Series of Diagnostic Test that Detects the Ever-Changing COVID-19 Variant Landscape

Seegene's High Multiplex Pcr Assay Capable of Detecting New Omicron Variant

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Seegene Inc. Unveils Fully Automated Molecular Testing System At the 2021 AACC

Price target decreased to ₩89,000

Consensus EPS estimates increase to ₩9,305

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Seegene Inc. Introduces its New Deployable Container Laboratory "Mobile Station", at the Medlab Middle East 2021

Investor sentiment improved over the past week

Price target decreased to ₩116,750

Seegene, Inc. Introduces an Exclusive Diagnostic System for Diagnosing Covid-19 Variants

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

Investor sentiment deteriorated over the past week